Short-Acting and Long-Acting Hypnotic Agent Combination for Sleep Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hypnotic agents either fail to induce or maintain restful sleep effectively without negatively impacting wakefulness periods, and there is a need for a combination that synergistically enhances sleep quality without adverse effects on waking phases.
Innovation Solution
A combination of a short-acting hypnotic agent and a long-acting hypnotic agent, where the short-acting agent is released immediately or over a prolonged period, and the long-acting agent is released immediately, creating a synergistic effect to improve sleep quality and duration without negatively affecting wakefulness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a short-acting hypnotic agent is administered, then sleep induction is improved, but sleep maintenance capability deteriorates
Solution Approach 1:
The patent combines a short-acting hypnotic agent (zolpidem, zaleplon, or zopiclone) with a long-acting hypnotic agent (eplivanserin, gaboxadol, or pregabalin) into a single pharmaceutical composition. This merging allows the short-acting component to rapidly induce sleep while the long-acting component sustains sleep maintenance, thereby resolving the contradiction between sleep induction speed and sleep maintenance duration.
2Duration of action of moving object
If a long-acting hypnotic agent is administered, then sleep maintenance is improved, but sleep induction speed deteriorates
Solution Approach 1:
The pharmaceutical composition merges a long-acting hypnotic agent (eplivanserin, gaboxadol, or pregabalin) with a short-acting hypnotic agent (zolpidem, zaleplon, or zopiclone). The long-acting component ensures sustained sleep maintenance while the short-acting component provides rapid sleep induction, thereby resolving the contradiction between sleep maintenance duration and sleep induction speed.
3Reliability
If high doses of hypnotic agents are administered, then sleep quality is improved, but adverse effects on wakefulness periods worsen
Solution Approach 1:
The patent changes the dosing parameters by administering low doses of both short-acting and long-acting hypnotic agents in combination, rather than high doses of a single agent. The short-acting agent is administered at 0.5-10 mg and the long-acting agent at 1-30 mg, creating a synergistic effect that improves sleep quality while minimizing adverse effects on wakefulness periods through reduced individual dosages.
4Ease of operation
If a single hypnotic agent is administered, then treatment simplicity is improved, but sleep quality and duration deteriorate
Solution Approach 1:
The patent merges multiple hypnotic agents with different durations of action into a single pharmaceutical composition that can be administered as one tablet or capsule. This maintains treatment simplicity while achieving superior sleep quality and duration through the synergistic combination of short-acting and long-acting components, eliminating the need for multiple separate medications.
Data Source
AI summary
The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist; and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine, an antagonist of receptors 5HT2A and a calcium ion modulator, for the treatment of sleep disorders. The invention also relates to galenic formulations containing said combination.